Shares of Genprex Inc. (GNPX) climbed 53% in morning trading on Wednesday after the company said the Food and Drug Administration had granted its experimental cancer treatment a fast-track designation. Genprex is testing the therapy in combination with AstraZeneca's (AZN.LN) Tagrisso for certain non-small cell lung cancer patients. AstraZeneca said in October that Tagrisso brought in $2.3 billion in sales year-to-date, an 82% jump compared to the year prior. Its stock was up 0.7% on Wednesday. Genprex plans to start a Phase I/II clinical trial for the investigational combination treatment. Genprex's stock is up 12% over the past year, while the S&P 500 has gained 24%.
-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
January 22, 2020 10:54 ET (15:54 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.